MSH|^~\&|PTH|RCH|||201911281134||ORU^R01|4116210|D|2.3|||AL|NE
PID|1||RC00006059|RC6052|LABTEST^ALASKA^ROLL||19900918|F||||||||||RC000066/17|9876521172
PV1|1|I
OBR|1|3259|00002366^17SS-290^PTH^17SS-290^3259||||20171025||||||LABTEST|201710251050|S^SURGICAL SPECIMEN^SURGICAL|||||17SS-290||201911281134|||SOUT
OBX|1|TX|Pathology Lab: Surrey Memorial Hospital
OBX|2|TX|Phone: (604)588-3384 Fax: (604)585-5562
OBX|3|TX| 
OBX|4|TX|Specimen Number: 17SS-290
OBX|5|TX| 
OBX|6|TX|DIAGNOSES
OBX|7|TX|test
OBX|8|TX| 
OBX|9|TX|SYNOPTIC REPORT
OBX|10|TX|--------  Ewing Sarcoma Biopsy, 1  --------
OBX|11|TX| 
OBX|12|TX|SPECIMEN COMMENT
OBX|13|TX|  Pertains To:                         test
OBX|14|TX| 
OBX|15|TX|SPECIMEN
OBX|16|TX|  Procedure:                           Core needle biopsy
OBX|17|TX| 
OBX|18|TX|TUMOUR
OBX|19|TX|  Tumour Site:                         Osseous
OBX|20|TX|    Osseous:                           Short bones of upper limb and associated
OBX|21|TX|                                       joints - test
OBX|22|TX|  Lymph-Vascular Invasion:             Not identified
OBX|23|TX| 
OBX|24|TX|ANCILLARY STUDIES
OBX|25|TX|  Best Tumour Block:                   test
OBX|26|TX|  Immunohistochemistry:                test
OBX|27|TX|  Cytogenetics Findings:               EWSR1 rearrangement present
OBX|28|TX|    EWSR1 Rearrangement:               Fusion partner not known
OBX|29|TX|    Method:                            Reverse transcriptase polymerase chain
OBX|30|TX|                                       reaction (RT-PCR)
OBX|31|TX| 
OBX|32|TX|ADDITIONAL PATHOLOGIC FINDINGS
OBX|33|TX|                                       test
OBX|34|TX| 
OBX|35|TX|COMMENT(S)
OBX|36|TX|                                       test
OBX|37|TX| 
OBX|38|TX|Based CAP eCC February 2019
OBX|39|TX|---------- End of Synoptic Report ----------
OBX|40|TX|--------  Ewing Sarcoma Resection, 2  --------
OBX|41|TX| 
OBX|42|TX|SPECIMEN COMMENT
OBX|43|TX|  Pertains To:                         test
OBX|44|TX| 
OBX|45|TX|CLINICAL
OBX|46|TX|  Preresection Treatment:              Radiation therapy performed
OBX|47|TX| 
OBX|48|TX|SPECIMEN
OBX|49|TX|  Procedure:                           Resection
OBX|50|TX| 
OBX|51|TX|TUMOUR
OBX|52|TX|  Tumour Site:                         Osseous
OBX|53|TX|    Osseous:                           Bone of limb, NOS - test
OBX|54|TX|  Tumour Size:                         4 x 2 x 2 cm
OBX|55|TX|  Primary Tumour Location:             Diaphysis
OBX|56|TX|  Lymph-Vascular Invasion:             Present
OBX|57|TX|  Treatment Effect:                    Necrosis not identified
OBX|58|TX| 
OBX|59|TX|MARGINS
OBX|60|TX|                                       Margins negative for tumour
OBX|61|TX|  Distance of Tumour From Closest Bone
OBX|62|TX|  Margin:                              4 cm
OBX|63|TX|  Distance of Tumour From Closest Soft
OBX|64|TX|  Tissue Margin:                       4 cm
OBX|65|TX|  Distance of Tumour From Closest
OBX|66|TX|  Other (e.g. parenchymal) Margin:     3 cm
OBX|67|TX| 
OBX|68|TX|LYMPH NODES, REGIONAL
OBX|69|TX|  Number of Lymph Nodes Examined:      4
OBX|70|TX|  Number of Lymph Nodes Involved:      2
OBX|71|TX| 
OBX|72|TX|PATHOLOGIC STAGE
OBX|73|TX|  Distant Metastasis (pM):             Present
OBX|74|TX|    Specify site(s), if known:         test
OBX|75|TX| 
OBX|76|TX|ADDITIONAL PATHOLOGIC FINDINGS
OBX|77|TX|                                       test
OBX|78|TX| 
OBX|79|TX|ANCILLARY STUDIES
OBX|80|TX|  Best Tumour Block:                   test
OBX|81|TX|  Immunohistochemistry:                test
OBX|82|TX|  Cytogenetic Findings:                EWSR1 rearrangement present
OBX|83|TX|    Fusion Partner Detection:          Fusion partner known
OBX|84|TX|      Fusion Partner Genes:            ERG
OBX|85|TX| 
OBX|86|TX|COMMENT(S)
OBX|87|TX|                                       test
OBX|88|TX| 
OBX|89|TX|Based on AJCC/UICC TNM, 7th edition; CAP eCC August 2016
OBX|90|TX|---------- End of Synoptic Report ----------
OBX|91|TX|--------  Ewing Sarcoma Resection, 3  --------
OBX|92|TX| 
OBX|93|TX|CLINICAL
OBX|94|TX|  Preresection Treatment:              Radiation therapy performed
OBX|95|TX| 
OBX|96|TX|SPECIMEN
OBX|97|TX|  Procedure:                           Resection
OBX|98|TX| 
OBX|99|TX|TUMOUR
OBX|100|TX|  Tumour Site:                         Extraosseous
OBX|101|TX|    Extraosseous:                      Peritoneum and / or retroperitoneum
OBX|102|TX|      Primary Tumour Site (peritoneum  Peritoneum, including omentum and mesentery
OBX|103|TX|      and / or retroperitoneum):       -  - test
OBX|104|TX|  Tumour Size:                         8 x 5 x 4 cm
OBX|105|TX|  Primary Tumour Location:             Medullary cavity
OBX|106|TX|  Lymph-Vascular Invasion:             Present
OBX|107|TX|  Treatment Effect:                    Necrosis present
OBX|108|TX|    Tumour necrosis:                   20 %
OBX|109|TX| 
OBX|110|TX|MARGINS
OBX|111|TX|                                       Margins negative for tumour
OBX|112|TX|  Distance of Tumour From Closest Bone
OBX|113|TX|  Margin:                              4 cm
OBX|114|TX|  Distance of Tumour From Closest Soft
OBX|115|TX|  Tissue Margin:                       3 cm
OBX|116|TX|  Distance of Tumour From Closest
OBX|117|TX|  Other (e.g. parenchymal) Margin:     4 cm
OBX|118|TX|  Comment:                             test
OBX|119|TX| 
OBX|120|TX|LYMPH NODES, REGIONAL
OBX|121|TX|  Number of Lymph Nodes Examined:      3
OBX|122|TX|  Number of Lymph Nodes Involved:      2
OBX|123|TX| 
OBX|124|TX|PATHOLOGIC STAGE
OBX|125|TX|  Distant Metastasis (pM):             Present
OBX|126|TX|    Site(s):                           test
OBX|127|TX| 
OBX|128|TX|ADDITIONAL PATHOLOGIC FINDINGS
OBX|129|TX|                                       testing testing
OBX|130|TX| 
OBX|131|TX|ANCILLARY STUDIES
OBX|132|TX|  Best Tumour Block:                   test
OBX|133|TX|  Immunohistochemistry:                test
OBX|134|TX|  Cytogenetic Findings:                EWSR1 rearrangement present
OBX|135|TX|    Fusion Partner Detection:          Fusion partner known
OBX|136|TX|      Fusion Partner Genes:            ERG
OBX|137|TX| 
OBX|138|TX|COMMENT(S)
OBX|139|TX|                                       test
OBX|140|TX| 
OBX|141|TX|Based CAP eCC February 2019
OBX|142|TX|---------- End of Synoptic Report ----------
OBX|143|TX|--------  Rhabdomyosarcoma, Undifferentiated sarcoma, Ectomesenchymoma, 4  --------
OBX|144|TX| 
OBX|145|TX|SPECIMEN COMMENT
OBX|146|TX|  Pertains To:                         test
OBX|147|TX| 
OBX|148|TX|SPECIMEN
OBX|149|TX|  Procedure:                           Marginal resection
OBX|150|TX|  Preoperative Treatment:              Chemotherapy given
OBX|151|TX| 
OBX|152|TX|TUMOUR
OBX|153|TX|  Tumour Site:                         Bladder / prostate
OBX|154|TX|  Histologic Type:                     Alveolar
OBX|155|TX|  Tumour Size:                         5 cm
OBX|156|TX|  Anaplasia:                           Focal (single or few scattered anaplastic
OBX|157|TX|                                       cells)
OBX|158|TX| 
OBX|159|TX|MARGINS
OBX|160|TX|  Margins:                             Negative for tumour
OBX|161|TX|    Distance of Tumour From Closest
OBX|162|TX|    Margin:                            5 cm
OBX|163|TX|    Margin:                            test
OBX|164|TX| 
OBX|165|TX|LYMPH NODES, REGIONAL
OBX|166|TX|  Number of Lymph Nodes Examined:      5
OBX|167|TX|  Number of Lymph Nodes Involved:      4
OBX|168|TX|  Distant Metastasis:                  Distant metastasis present
OBX|169|TX|    Site(s):                           test
OBX|170|TX| 
OBX|171|TX|PATHOLOGIC STAGE
OBX|172|TX|  The Intergroup Rhabdomyosarcoma      Any size primary tumour, with or without
OBX|173|TX|  Study Postsurgical Clinical Grouping regional lymph node involvement, with
OBX|174|TX|  System:                              distant metastases, without respect to
OBX|175|TX|                                       surgical approach to primary tumour.
OBX|176|TX|  Modified Site, Size, Metastasis
OBX|177|TX|  Staging for Rhabdomyosarcoma:
OBX|178|TX|    Stage IV:                          Distant metastases present
OBX|179|TX| 
OBX|180|TX|ANCILLARY STUDIES
OBX|181|TX|  Best Tumour Block:                   test
OBX|182|TX|  Fusion Status:                       FOXO1 rearrangement present
OBX|183|TX|    FOXO1 Rearrangement:               Amplification status
OBX|184|TX|    Method:                            FISH
OBX|185|TX| 
OBX|186|TX|COMMENT(S)
OBX|187|TX|                                       test
OBX|188|TX| 
OBX|189|TX|Based on The Intergroup Rhabdomyosarcoma Study Postsurgical Clinical Grouping System
OBX|190|TX|---------- End of Synoptic Report ----------
OBX|191|TX| 
OBX|192|TX|SPECIMEN SUBMITTED
OBX|193|TX|TESTING
OBX|194|TX| 
OBX|195|TX|CLINICAL INFORMATION
OBX|196|TX|TESTING
OBX|197|TX| 
OBX|198|TX|GROSS DESCRIPTION
OBX|199|TX|TESTING
OBX|200|TX| 
OBX|201|TX|MICROSCOPIC DESCRIPTION
OBX|202|TX|TESTING
OBX|203|TX|                                                    ____________________________________
OBX|204|TX|                                                    Teresa Chow
OBX|205|TX|                                                    Electronically signed: 28/Nov/2019
OBX|206|TX| 
OBX|207|TX|--------------------------------------------------------------------------------------------
OBX|208|TX| 
OBX|209|TX|